Infanrix Hexa - direct healthcare professional communication (DHPC)

Diphtheria toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis B surface antigen / poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain)) / Haemophilus influenzae type b polysaccharide / tetanus toxoid

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Infanrix hexa Packaging issue potentially impacting the sterility of needle softpacks of Infanrix hexa

Key facts

• Medicine name:
  Infanrix Hexa
• Active substance:
  • Diphtheria toxoid
  • Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin)
  • hepatitis B surface antigen
  • poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain))
  • Haemophilus influenzae type b polysaccharide
  • tetanus toxoid
• Therapeutic area (MeSH):
  • Hepatitis B
  • Immunization
  • Meningitis
  • Haemophilus
  • Whooping Cough
  • Poliomyelitis
  • Diphtheria
  • Tetanus
• DHPC type:
  Quality defect
• Human ATC codes:
  J07CA09
• Dissemination date:
  10/10/2024